On May 28, the NMPA website announced that Hengrui Pharma’s Class 1 new drug SHR4640 has been approved for marketing in patients with gout and hyperuricemia. SHR4640 (R&D code: SHR4640; also known as Ruzinurad) is a highly selective small-molecule inhibitor…
On May 28, the NMPA website shows that Beijing Northland Biotechnology’s Class 1 new drug **NL003** is approved for market in China for the treatment of ulcers caused by critical limb ischemia (CLI). NL003 injection is a novel plasmid-based gene…
On May 21, the NMPA website announced that Johnson & Johnson’s innovative drug with a novel mechanism,Nipocalimab Injection (trade name:IMAAVY®), officially received marketing approval from the National Medical Products Administration (NMPA). It can be used in combination with conventional treatment…
On May 21, the NMPA website announced that Yangtze River Pharmaceutical Group (YRPG)’s Class 1 new drug Fazamorexant Tablets had been approved for marketing in China for the treatment of insomnia. This is the first domestic dual orexin receptor antagonist approved in…
Onradivir granules (generic name: Onradivir, research code: ZSP1273) are a Class 1 chemical innovative drug independently developed by Raynovent in Guangdong, China, and represent the world’s first pediatric formulation of an influenza A virus RNA polymerase PB2 inhibitor. On May 22,…
On May 14th, Kangfang Biotechnology announced that its independently developed new generation anti-CD47 humanized IgG4 monoclonal antibody, Lefacizumab (AK117), combined with Azacitidine+Vinaccra, is a randomized, double-blind, controlled phase II study (AK117-206) for the treatment of previously untreated acute myeloid leukemia…
Major MS Data Presented at ECTRIMS: Long-Term OCREVUS Safety Confirmed; Fenebrutinib Phase II Shows Near-Complete Disease Suppression Introduction At the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Roche presented a substantial…
Major Step Forward in Endocrine-Resistant Breast Cancer Treatment Roche has announced positive results from its Phase III evERA study, signaling a potential new treatment option for patients with Estrogen Receptor-positive (ER+), HER2-negative advanced or metastatic breast cancer whose disease has…
Your choices can be overwhelming. You’ve got over a dozen options to pick from — each with its pros and cons. When it comes right down to it, the best birth control is the method you’re most likely to use. But…
It can be hard finding back pain treatments that offer lasting relief, or any relief. That’s why a surprising new study, published Wednesday, is drawing public and clinical attention, showing that adults with disabling low-back pain who completed just eight…